[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].

Sorry, there's nothing here.

Cite this paper

@article{Taira1980TheBF, title={[The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)].}, author={Koichiro Taira and Yoko Yasuda and Tomohiko Shindo and Noriyuki Mitani and Akiko Akazawa}, journal={Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan}, year={1980}, volume={100 3}, pages={272-9} }